Feb 1 2010
DSG’s eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current phase 2 and phase 2a clinical trials for treatments of progressive and chronic kidney disease. The company uses DSG’s eCaseLink™ to automate and manage the data collection process during the clinical trial lifecycle. In addition, DSG combines data management services with eCaseLink™ to seamlessly optimize data collection and analysis.
“Partnering with innovative drug companies like this, helping to find ways to help those suffering from progressive and chronic kidney disease, is an ideal way for DSG’s unique eCaseLink™ EDC system to be employed in clinical trials”
The result is clean clinical trial data, collected and analyzed efficiently. This accelerates the clinical trial process, helping to safely speed these treatments to those who need them.
The phase 2 study, is a new treatment that may help people in the early stage of diabetic nephropathy, a progressive kidney disease. The second study, currently in phase 2a, is a treatment for anemia in chronic kidney disease.
The two clinical trials demand a data capture and management solution that speeds time-to-market while complying with all appropriate regulatory procedures. eCaseLink™ EDC provides real-time, clean data, which facilitates quick data review, reporting and decision making for the company.
The eCaseLink™ system is a critical tool for the investigator site and monitoring personnel, in part because it greatly reduces the amount of time it takes to “lock” the clinical database. Database lock occurs once all data has been verified and cleaned through the data management process. Once “locked,” the study’s statistical analysis is performed and results are reported.
“Partnering with innovative drug companies like this, helping to find ways to help those suffering from progressive and chronic kidney disease, is an ideal way for DSG’s unique eCaseLink™ EDC system to be employed in clinical trials,” said Tony Varano, CEO of DSG.
Novel multi-biomarker approach enhances chronic kidney disease risk assessment